Werewolf Therapeutics (Werewolf Therapeutics) EBIT : $-37.20 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics EBIT?

Werewolf Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-15.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-37.20 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Werewolf Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -138.20%. Werewolf Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -420.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Werewolf Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -58.35%.

Werewolf Therapeutics EBIT Historical Data

The historical data trend for Werewolf Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics EBIT Chart

Werewolf Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-9.94

-22.40

-50.09

-53.81

-34.23

Werewolf Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial													-11.81	-6.07	-9.25	-6.69	-15.19

Competitive Comparison of Werewolf Therapeutics's EBIT

For the Biotechnology subindustry, Werewolf Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Werewolf Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's EV-to-EBIT falls into.

Werewolf Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.20 Mil.

Werewolf Therapeutics (NAS:HOWL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Werewolf Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-68.648 * ( 1 - 0% )	/	( (49.272	+	50.071)	/ 2 )
=	-68.648	/	49.6715
=	-138.20 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	174.833	-	6.569	-	( 134.343	-	max(0, 19.378	-	138.37	+	134.343	))
=	49.272

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	177.6	-	6.459	-	( 139.189	-	max(0, 21.214	-	142.284	+	139.189	))
=	50.071

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Werewolf Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-60.76	/	( ( (14.846 + max(-8.426, 0))	+	(14.041 + max(-5.991, 0)) )	/	2 )
=	-60.76	/	( ( 14.846	+	14.041 )	/	2 )
=	-60.76	/	14.4435
=	-420.67 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.677)	-	(6.569	+	0.907	+	3.627)
=	-8.426

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.32)	-	(6.459	+	0.502	+	1.35)
=	-5.991

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Werewolf Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-37.196	/	63.741
	=	-58.35 %

Werewolf Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472

Website

https://www.werewolftx.com

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake	officer: Chief Technology Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard	officer: Chief Operating Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc	10 percent owner	800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin	10 percent owner	6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin	director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520